SG Americas Securities
OMED

SG Americas Securities’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

SG Americas Securities’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-58,626
Closed -$540K – 3796
2017
Q1 		$540K Buy
58,626
+44,419
+313% +$390K ﹤0.01% 1800
2016
Q4 		$110K Buy
+14,207
New +$131K ﹤0.01% 2811
2015
Q3 		– Sell
-5,764
Closed -$130K – 3085
2015
Q2 		$130K Buy
+5,764
New +$142K ﹤0.01% 2214

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SG Americas Securities's OMED Position: Q2 2017 in Review

SG Americas Securities sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 58,626 shares — an estimated $540K sold.

SG Americas Securities first reported a position in OMED in Q2 2015 and held it in 3 quarters. The position peaked at $540K in Q1 2017. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

  • SG Americas Securities reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • SG Americas Securities sold 58,626 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $540K.
  • SG Americas Securities first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2015 and held it in 3 quarters.
  • SG Americas Securities's OncoMed Pharmaceuticals, Inc. position peaked at $540K in Q1 2017.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on SG Americas Securities's 13F filing for Q2 2017, filed 3 Aug 2017.